Showing 3321-3330 of 5956 results for "".
- Frontera Therapeutics Completes $160 Million Series B Financing to Fund Clinical Development and Manufacturing Capabilitieshttps://modernod.com/news/frontera-therapeutics-completes-160-million-series-b-financing-to-fund-clinical-development-and-manufacturing-capabilities/2480975/Frontera Therapeutics announced successful completion of a $160 million Series B funding round. In addition, Frontera announced that the FDA has accepted the company’s investigational new drug (IND) application to initiate a first-in-human clinical trial of FT
- Glasgow Eye Department Now Using Ocular Simulation Training Through DRV Systemhttps://modernod.com/news/glasgow-eye-department-now-using-ocular-simulation-training-through-drv-system/2480954/Simulation exposure is now an essential component of the Royal College of Ophthalmologists’ Ophthalmic Specialist Training curriculum prior to real-life surgery, according to a news release from Vision Engineering Group, a maker of ergonomic stereo optical and digital instruments. &nbs
- Nicox Announces Publication of NCX 470 Results Demonstrating Improvements to Ocular Hemodynamics and Retinal Cell Physiologyhttps://modernod.com/news/nicox-announces-publication-of-ncx-470-results-demonstrating-improvements-to-ocular-hemodynamics-and-retinal-cell-physiology-1/2480951/Nicox SA announced that the results from studies on the beneficial effects of NCX 470 in a nonclinical model of endothelin-1 (ET-1)-induced ischemia/reperfusion damage of the optic nerve head and retina have been published online in the peer-reviewed Journal of Ocular Pharmacology and Therape
- MeiraGTx Announces Topline Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Vision in XLRP Patientshttps://modernod.com/news/meiragtx-announces-positive-topline-data-from-the-mgt009-phase-12-clinical-study-demonstrating-safety-and-improvement-in-vision-in-xlrp-patients/2480936/MeiraGTx Holdings announced topline data from the phase 1/2 clinical study MGT009 (
- OliX Pharmaceuticals Subsidiary mCureX Announces mRNA Technology Collaboration with ToolGen for Rare Eye Diseasehttps://modernod.com/news/olix-pharmaceuticals-subsidiary-mcurex-announces-mrna-technology-collaboration-with-toolgen-for-rare-eye-disease/2480920/OliX Pharmaceuticals, a\ developer of RNAi therapeutics, announced that the company’s subsidiary, mCureX Therapeutics, has recently signed a contract for joint research with ToolGen to advance the development of gene therapy for rare eye diseases, leveraging mCureX’s mRNA technol
- CORE Study Shows Importance of Rub and Rinse Regimen for Coronavirus Removal from Contact Lens Materialshttps://modernod.com/news/core-study-shows-importance-of-rub-and-rinse-regimen-for-coronavirus-removal-from-contact-lens-materials/2480905/A new study conducted by the
- Aurion Biotech Appoints Michael Goldstein, MD, as President and Chief Medical Officerhttps://modernod.com/news/aurion-biotech-appoints-dr-michael-goldstein-as-president-and-chief-medical-officer/2480904/Aurion Biotech announced it has appointed Michael Goldstein, MD, as president and chief medical officer. Dr. Goldstein will lead the company’s clinical strategy, development and operations; medical affairs; and manufacturing and quality teams for its first product candidate, a cel
- NIH: Gene Therapy for Rare Eye Disease Safe But Lacks Efficacy in Early Trialhttps://modernod.com/news/nih-gene-therapy-for-rare-eye-disease-safe-but-lacks-efficacy-in-early-trial/2480896/A 28-patient phase 1 gene therapy clinical trial for the degenerative retinal disease Leber hereditary optic neuropathy (LHON) found no significant safety concerns; however, treatment failed to improve or slow vision loss, with even the highest dose. LHON affects the optic nerve, which carries vi
- The Vision Council Announces that Version 3.13 of the Data Communication Standard is Now Availablehttps://modernod.com/news/the-vision-council-announces-that-version-313-of-the-data-communication-standard-is-now-available/2480893/The Vision Council announced the publication of Version 3.13 of the Standard for Data Communications. The standard, which is used by manufacturers of optical lab equipment and producers of software used in optical labs, was developed by The Vision Council’s Lens Proce
- Market Scope: Global PC-IOL Demand Rises Modestly, Soars in a Few Countrieshttps://modernod.com/news/market-scope-global-pc-iol-demand-rises-modestly-soars-in-a-few-countries/2480888/Presbyopia-correcting IOLs experienced steady global growth in 2021 and record-breaking growth in a handful of countries, according to a Market Scope re